HC Wainwright cut shares of TCR2 Therapeutics (NASDAQ:TCRR – Get Rating) from a buy rating to a neutral rating in a research report sent to investors on Tuesday, The Fly reports.
Several other research firms also recently weighed in on TCRR. Piper Sandler upped their price objective on shares of TCR2 Therapeutics from $8.00 to $10.00 and gave the stock an overweight rating in a report on Thursday, January 5th. EF Hutton Acquisition Co. I assumed coverage on shares of TCR2 Therapeutics in a report on Thursday, January 5th. They set a hold rating and a $2.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of Hold and an average price target of $10.75.
TCR2 Therapeutics Trading Down 1.2 %
TCRR opened at $1.60 on Tuesday. The company’s fifty day moving average price is $1.26 and its two-hundred day moving average price is $1.55. TCR2 Therapeutics has a 1-year low of $0.82 and a 1-year high of $3.88. The company has a market cap of $61.86 million, a price-to-earnings ratio of -0.52 and a beta of 1.90.
Institutional Trading of TCR2 Therapeutics
TCR2 Therapeutics Company Profile
TCR2 Therapeutics, Inc is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development.
- Get a free copy of the StockNews.com research report on TCR2 Therapeutics (TCRR)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Receive News & Ratings for TCR2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TCR2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.